Chuanliang Cui
Peking University(CN)Peking University Cancer Hospital(CN)Ministry of Education(ET)
Publications by Year
Research Areas
Cutaneous Melanoma Detection and Management, Cancer Immunotherapy and Biomarkers, Melanoma and MAPK Pathways, CAR-T cell therapy research, Immunotherapy and Immune Responses
Most-Cited Works
- → Phase II, Open-Label, Single-Arm Trial of Imatinib Mesylate in Patients With Metastatic Melanoma Harboring c-Kit Mutation or Amplification(2011)674 cited
- → Clinical presentation, histology, and prognoses of malignant melanoma in ethnic Chinese: A study of 522 consecutive cases(2011)399 cited
- → Whole-genome landscape of mucosal melanoma reveals diverse drivers and therapeutic targets(2019)326 cited
- → Open-label, Multicenter, Phase II Study of RC48-ADC, a HER2-Targeting Antibody–Drug Conjugate, in Patients with Locally Advanced or Metastatic Urothelial Carcinoma(2020)271 cited
- → Prevalence of BRAF V600E mutation in Chinese melanoma patients: Large scale analysis of BRAF and NRAS mutations in a 432-case cohort(2011)264 cited
- → Large-Scale Analysis of KIT Aberrations in Chinese Patients with Melanoma(2011)251 cited